TY - JOUR
T1 - Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis
AU - Szalardy, L.
AU - Zadori, D.
AU - Tánczos, E.T.
AU - Simu, M.
AU - Bencsik, K.
AU - Vecsei, L.
AU - Klivenyi, P.
PY - 2013
Y1 - 2013
N2 - Peroxisome proliferator-activated receptor gamma (PPAR¿), a ligand-activated transcriptional factor involved in the regulation of glucose and lipid metabolism, has gained interest as a potential therapeutic target in multiple sclerosis (MS) due to its potent immunoregulatory properties and the therapeutic efficacy of its ligands in experimental autoimmune encephalitis (EAE). Elevated expression of PPAR¿ has been observed in the spinal cord of EAE mice and in an in vitro model of antigen-induced demyelination; however, no reports have yet been available on the PPAR¿ status in the central nervous system of human individuals with MS. Aiming to identify a possible alteration, the present study assessed the levels of PPAR¿ protein in the cerebrospinal fluid (CSF) of MS patients via ELISA technique. We report a pronounced elevation in the CSF levels of PPAR¿ in MS patients ( n=. 35) compared to non-inflammatory controls ( n=. 22). This elevation was independent of blood-CSF barrier integrity, but correlated with CSF white blood cell count and IgG index, associating the observed elevation with neuroinflammation. Controlling for potential confounders, the CSF levels of PPAR¿ further displayed a moderate but significant association with clinical severity. Corroborating with prior experimental findings, these results may contribute to our understanding about the role of PPAR¿ in MS, and may implicate this protein as a potential CSF biomarker of the disease.
Keywords: Biomarker; Cerebrospinal fluid; ELISA; Multiple sclerosis; Peroxisome proliferator-activated receptor gamma
AB - Peroxisome proliferator-activated receptor gamma (PPAR¿), a ligand-activated transcriptional factor involved in the regulation of glucose and lipid metabolism, has gained interest as a potential therapeutic target in multiple sclerosis (MS) due to its potent immunoregulatory properties and the therapeutic efficacy of its ligands in experimental autoimmune encephalitis (EAE). Elevated expression of PPAR¿ has been observed in the spinal cord of EAE mice and in an in vitro model of antigen-induced demyelination; however, no reports have yet been available on the PPAR¿ status in the central nervous system of human individuals with MS. Aiming to identify a possible alteration, the present study assessed the levels of PPAR¿ protein in the cerebrospinal fluid (CSF) of MS patients via ELISA technique. We report a pronounced elevation in the CSF levels of PPAR¿ in MS patients ( n=. 35) compared to non-inflammatory controls ( n=. 22). This elevation was independent of blood-CSF barrier integrity, but correlated with CSF white blood cell count and IgG index, associating the observed elevation with neuroinflammation. Controlling for potential confounders, the CSF levels of PPAR¿ further displayed a moderate but significant association with clinical severity. Corroborating with prior experimental findings, these results may contribute to our understanding about the role of PPAR¿ in MS, and may implicate this protein as a potential CSF biomarker of the disease.
Keywords: Biomarker; Cerebrospinal fluid; ELISA; Multiple sclerosis; Peroxisome proliferator-activated receptor gamma
U2 - 10.1016/j.neulet.2013.08.069
DO - 10.1016/j.neulet.2013.08.069
M3 - Article
C2 - 24021801
VL - 554
SP - 131
EP - 134
JO - Neuroscience Letters
JF - Neuroscience Letters
SN - 0304-3940
ER -
